Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Cabaletta Bio (CABA) to $13 from $14 and keeps an Overweight rating on the shares. Rese-cel execution remains on track with data updates across multiple indications and next generation innovations expected later this year, the analyst tells investors in a research note. The firm added that it is encouraged by ongoing progress and looks ahead tot continued positive updates throughout 2026.